AI Utilization Agreement for Arrhythmia and Heart Failure Diagnosis
Daewoong Pharmaceutical is partnering with KMI Korea Medical Institute to advance early diagnosis of arrhythmia and heart failure using artificial intelligence (AI).
Daewoong Pharmaceutical announced on the 21st that on the 19th, it signed an agreement with KMI Korea Medical Institute at Daewoong Pharmaceutical headquarters in Gangnam-gu, Seoul, to supply an AI electrocardiogram examination solution. Kwon Jun-myeong, CEO of Medical AI; Lee Sang-ho, Chairman of KMI Korea Medical Institute; Lee Chang-jae, CEO of Daewoong Pharmaceutical; Lee Young-shin, CEO of Sears Technology. (From left) Photo by Daewoong Pharmaceutical
On the 19th, Daewoong Pharmaceutical announced on the 21st that it signed a memorandum of understanding (MOU) with KMI Korea Medical Institute at Daewoong Pharmaceutical’s headquarters in Gangnam-gu, Seoul, to supply AI electrocardiogram (ECG) examination solutions. In addition to representatives from both companies, the solution developers, Seers Technology and Medical AI, also participated in the signing ceremony.
Through this agreement, the two parties plan to develop customized examination methods that consider the examinees’ age and underlying diseases by utilizing wearable medical devices and AI solutions. Specifically, they will collaborate to apply AI technology to the areas of arrhythmia and heart failure, which have been difficult to screen, to increase early diagnosis rates and provide the latest medical services. They aim to introduce the solution and develop the system by January 2024, with the agreement period set for one year.
Daewoong Pharmaceutical will be responsible for supplying 'MobiCare' and 'AiTiA LVSD' to KMI’s eight comprehensive health screening centers nationwide. Daewoong Pharmaceutical stated that it is accelerating preparations by forming an internal task force (TF) team to commence full-scale operations.
Seers, the supplier of MobiCare, a wearable ECG solution capable of continuous monitoring for nine consecutive days, will provide a customized specialized system for KMI that can conduct examinations for more than 800 people per day. Medical AI, the developer of the ECG analysis AI software 'AiTiA LVSD,' plans to complete on-site diagnostic preparations at all centers by next month, starting with KMI Jeju Screening Center at the end of this month.
KMI plans to further strengthen its smart healthcare environment for partner companies and customers by introducing differentiated cardiac examination solutions. Established in 1985, KMI operates health screening centers in eight regions nationwide and is engaged in activities aimed at early disease detection, prevention, and promoting public health.
Lee Sang-ho, Chairman of KMI, said, "Through this agreement with Daewoong Pharmaceutical, a leading healthcare company in Korea, and companies possessing top AI technology, KMI has taken a significant leap forward as a leading medical institution for the advancement of public health. In particular, the introduction of AI ECG examinations will be an opportunity to elevate the level of cardiac examinations in the screening field and to advance the system."
Lee Chang-jae, CEO of Daewoong Pharmaceutical, stated, "This agreement with KMI, a representative screening institution for public health promotion, will create a new paradigm in the areas of arrhythmia and heart failure, where early detection has been difficult due to limitations in diagnostic methods. Daewoong Pharmaceutical will do its best to provide KMI with more advanced examination solutions in collaboration with Seers Technology and Medical AI."
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
